CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

NCT05558124 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Vyxeos
DRUG: Gemtuzumab Ozogamicin

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

Jazz Pharmaceuticals